

1 **Molecular Epidemiology, Risk Factors and Clinical Outcomes of Carbapenem- and**
2 **Polymyxin-Resistant Gram-negative Bacterial Infections in Pregnant Women and**
3 **Infants: A Systematic Review**

4 John Osei Sekyere^{1#} and Melese Abate Reta¹

5 ¹Department of Medical Microbiology, University of Pretoria, 0084 Prinshof Pretoria, South
6 Africa

7 #Address correspondence to jod14139@gmail.com

8 Tweet: “*Clonal outbreaks of carbapenem- & colistin-resistant bacteria are common in neonatal intensive care*
9 *units, causing very high mortalities. However, effective antibiotic therapy and infection control can prevent*
10 *these deaths*”

11 **Highlights**

- 12 • Carbapenems & polymyxins are last-resort antibiotics used for multidrug-resistant
13 infections
- 14 • Resistance to these two agents are reported in infants & pregnant women
- 15 • *K. pneumoniae*, *E. coli*, and *A. baumannii* are the most common pathogens
- 16 • Carbapenem & polymyxin resistance cause outbreaks with high infant mortalities
- 17 • Appropriate treatment & infection control can outbreaks & save lives

18

19

20

21

22

23 **Abstract**

24 **Background.** Carbapenems and polymyxins are last-resort antibiotics used to treat
25 multidrug-resistant bacterial infections. However, resistance is increasing, even in vulnerable
26 groups such as pregnant women and infants, for whom therapeutic options are limited.

27 **Method.** Using a diversity of databases, the literature was searched for studies investigating
28 carbapenem and polymyxin resistance in pregnant women and infants (< 5 years).

29 **Result.** A final set of 73 manuscripts were used. In almost all countries,
30 carbapenem/polymyxin-resistant *Klebsiella pneumoniae*, *Escherichia coli*, and *Acinetobacter*
31 *baumannii* infect and/or colonizes neonates and pregnant women, causing periodic outbreaks
32 with very high infant mortalities. Plasmid-borne *bla*_{NDM}, *bla*_{KPC}, *bla*_{OXA-48}, *bla*_{IMP}, *bla*_{VIM} and
33 *bla*_{GES-5} and ompK35/36 downregulation in clonal strains accelerate the horizontal and
34 vertical transmission of carbapenem resistance in these pathogens. High prevalence of
35 carbapenem/polymyxin resistance and carbapenemases were present in India, China,
36 Pakistan, Thailand, Taiwan, Turkey, Egypt, Italy, USA, South Africa, Algeria, Ghana, and
37 Madagascar. Factors such as antibiotic therapy, prolonged hospitalization, invasive
38 procedures, mother/infant colonization, mechanical ventilation, low-birth weight and preterm
39 state placed infants at high risk of carbapenem/polymyxin-resistant infections. Infant
40 mortalities ranged from 0.2% to 36.8% in different countries.

41 **Conclusion.** Use of polymyxins to treat carbapenem-resistant infections is selecting for
42 resistance to both agents, restricting therapeutic options for infected infants and pregnant
43 women. However, appropriate infection control and antibiotic therapy can contain outbreaks
44 and clear these infections. Antibiotic stewardship, periodic rectal and vaginal screening, and
45 strict infection control practices in neonatal ICUs are necessary to forestall future outbreaks
46 and deaths.

47 **Keywords:** Carbapenem; polymyxin; colistin; carbapenemase; antibiotic resistance; pregnant
48 women; infants; neonates.

49 **Introduction**

50 Resistance to antimicrobials remain a major challenge to public health, veterinary medicine,
51 agriculture and aquaculture globally, owing to the limited or no therapeutic option available
52 to treat multidrug-resistant (MDR) infections¹⁻⁵. To avoid depleting our antibiotics arsenals
53 against infectious pathogens, certain agents are reserved as last-line drugs to fight difficult-to-
54 treat infections⁶⁻⁸. Currently, carbapenems, polymyxins (colistin) and tigecycline are used as
55 reserved agents for MDR infections^{9,10}. However, the continual use of carbapenems and
56 polymyxins to treat bacterial infections resistant to penicillins, cephalosporins, and
57 carbapenems are increasing the rate of resistance to these last-resort antibiotics^{2,4,9,11}. The
58 emergence of carbapenem- and/or polymyxin-resistant MDR infections is thus limiting
59 therapeutic options and increasing hospital stay, healthcare costs, morbidity, and mortality¹²⁻
60 ¹⁴. Subsequently, the WHO has classified carbapenem-resistant Gram-negative bacteria (CR-
61 GNB) as critical priority pathogens for which novel antibiotics are urgently needed^{15,16}.

62 Pregnant women and infants (below 5 years old) are a vulnerable population with regards to
63 bacterial infections due to their unbalanced and less matured immune system, respectively,
64 and the limited therapeutic options available to them¹⁷⁻¹⁹. Hence, the presence of MDR
65 carbapenem and/or polymyxin-resistant infections among pregnant women and infants make
66 them more susceptible to the ramifications of the infection^{13,19,20}. Whereas several studies
67 have reported on pregnant women colonized with CR-GNB than infected by it, there is a risk
68 of colonized pregnant women transferring these CR-GNB to their new borns^{19,21-24}. It is
69 therefore not surprising that numerous studies report on CR-GNB- and polymyxin-resistant
70 Gram-negative bacteria (PR-GNB)-infected neonates than colonized ones^{20,23,25,26}. Further,

71 there have been abundant reports of clonal and polyclonal CR-GNB outbreaks in neonatal
72 intensive care units (NICUs) globally, claiming the lives of several neonates as a result ^{18,27-}
73 ²⁹. This makes neonates more susceptible to CR-GNB and PR-GNB infections with their
74 associated morbidity and mortality ^{17-20,30} .

75 Notably, CR-GNB and PR-GNB carry other antibiotic resistance genes (ARGs) on mobile
76 plasmids, transposons, integrons, integrative conjugative elements (ICE), and insertion
77 sequences (ISs) that facilitate the horizontal transmission of these ARGs between species and
78 clones ^{13,20,31-33} . Specifically, extended-spectrum β -lactamases (ESBLs), fluoroquinolones,
79 aminoglycosides, tetracycline, sulphamethoxazole-trimethoprim, and macrolide ARGs are
80 also found in CR-GNB and PR-GNB. Hence, under antibiotic selection pressure, MDR
81 plasmids and clones proliferate, leading to outbreaks ^{10,27,34,35} . It is thus not surprising that
82 most neonatal CRE infections occur in NICUs during clonal outbreaks in which the isolates
83 harbour multiple ARGs on mobile plasmids ^{20,25,26,30,36,37} . Analyses of the data obtained from
84 this study confirms this observation.

85 ***Evidence before this review***

86 A thorough review of the literature showed the absence of a review addressing carbapenem
87 and polymyxin resistance among pregnant women and neonates. Only one review addressed
88 carbapenem-resistance among Gram-negative bacteria (GNB) in children¹⁴ whilst another
89 only addressed CRE-causing neonatal sepsis in China³⁸ . Thus, this is the first work to
90 systematically review and statistically analyse the literature on carbapenem and polymyxin
91 resistance among pregnant women and infants.

92 ***Literature & databases search strategy***

93 All literature published in English were searched on Medline/PubMed, Web of Science,
94 ScienceDirect, HINARI, Cochrane library electronic databases, and Google scholar using the

95 following search words: "Gram-negative bacteria", "epidemiology", "prevalence",
96 "incidence", "risk factors", "determinant", "associated factors", "carbapenem", "carbapenem
97 resistance", "colistin", "polymyxin resistance", "carbapenem-resistant Gram-negative
98 bacteria", "colistin-resistant Gram-negative bacteria", "carbapenem resistance determinants",
99 "carbapenem resistance genotypes", "carbapenem resistance mechanisms", "colistin
100 resistance determinants", "colistin resistance genotypes", "colistin resistance mechanisms",
101 "infants", "neonates", "children" and "pregnant women". These search words were further
102 paired with each other in a factorial fashion and search strings were implemented using
103 "AND" and "OR" Boolean operators. "OR" was used between "colistin" and "polymyxin" as
104 in "colistin OR polymyxin". No other filters were employed and the search was carried out
105 up to 30th September 2020. Both authors undertook the literature search, title and abstract
106 screening and resolved outstanding discrepancies by consensus, using the inclusion and
107 exclusion criteria.

108 ***Inclusion and exclusion criteria***

109 All articles addressing the following were included: 1) molecular testing of carbapenem- and
110 polymyxin (colistin)-resistant GNB isolated from pregnant women and/or infants; 2)
111 phenotypic antimicrobial sensitivity testing (AST) of carbapenem and polymyxin (colistin)-
112 resistant GNB isolated from pregnant women and/or infants; 3) epidemiology (incidence,
113 prevalence, risk factors and/or clinical outcomes) of carbapenem and/or polymyxin (colistin)
114 resistance in pregnant women and/or infants (<5years old); 4) articles on pregnant women
115 and infants with carbapenem or polymyxin (colistin)-resistant infections or colonization.
116 Articles reporting on carbapenem-and/or polymyxin (colistin)-resistant GNB isolated from
117 non-pregnant women and/or infants greater than 5 years old were excluded.

118 ***Statistical analyses***

119 Data on isolation country, year of isolation, carbapenem and polymyxin resistance profiles,
120 GNB species and clones, carbapenem and polymyxin resistance mechanisms, age, sex,
121 clinical history, colonization or infection, clinical history, previous and current medications,
122 clinical outcomes, mortality rate and risk factors were extracted from the included articles
123 and populated into Microsoft Excel. Further analyses were undertaken to compute isolation
124 rates, prevalence, resistance rates, and mortality rates per country (Tables S1-S3).

125 **Results**

126 ***Included studies and samples***

127 A total of 1427 articles were retrieved from the various databases, of which 73 studies from
128 28 countries worldwide were finally included for the qualitative and quantitative analyses
129 (Figure S1). Studies describing carbapenem resistance in infants (n = 65 studies) were from
130 24 countries, involved 49 154 infants (< 5 years), and resulted in the isolation of 11 441 GNB
131 cultures with 23.3% isolation rate (Table S1). Carbapenem resistance in pregnant women (n =
132 7 studies) were reported from six countries among 1892 pregnant women; this resulted in 285
133 GNB cultures and an isolation rate of 15.1% (Table S2). Included studies on polymyxin
134 resistance (n = 7) were mainly in infants (n = 16 556), with one being from a pregnant
135 woman³⁹; 1345 GNB cultures were obtained, yielding an isolation rate of 8.1% (Table S3)
136 (Figure S2).

137 Fifty studies on infants involved carbapenem resistance infections, 11 involved colonization
138 by CR-GNB, and four involved both infection and colonization. At least 22 studies out of the
139 50 describing GNB infections in neonates involved sepsis cases (Table S1). Notably, all the
140 studies on PR-GNB in infants also involved infection cases with no colonizations (Table S3).
141 However, six of the seven studies on CR-GNB in pregnant women were mainly colonization

142 cases with no infections, with only one study being an infection case in the USA (Table S2).

143 There were higher GNB isolations from India, Bangladesh, Pakistan, Morocco, China,

144 Turkey, South Africa, USA, and Cambodia than from the other countries (Figure S2).

145 *Species, clones, and resistance rates*

146 On a per country basis, *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*,

147 *Enterobacter sp.* (cloacae), and *Pseudomonas aeruginosa* were the most dominant species

148 causing infections or colonization in infants and pregnant women, with *Citrobacter sp.*,

149 *Proteus sp.*, *Morganella sp.*, *Serratia sp.*, and *Salmonella sp.* being some of the less common

150 species (Figure 1). Although these species differed in terms of prevalence per country, *E.*

151 *coli*, *K. pneumoniae* and *A. baumannii* were the most common in almost all countries whilst

152 *Pseudomonas aeruginosa* were highly prevalent in Italy, Nepal, USA, Turkey, and Kenya.

153 The dominant clones of the various species were mainly localized within countries with few

154 clones being observed across countries. For instance, only *K. pneumoniae* ST11 (in India,

155 China, and multiple settings), *K. pneumoniae* ST15 (India, China, and Nepal), *K. pneumoniae*

156 ST17 (Ghana and China) were observed across countries. Relatively few studies

157 characterized the CR-GNB isolates to determine their clonality whilst others used PFGE or

158 REP-PCR, limiting an effective international clonal analyses (Figure 2). Yet, the various

159 clones identified within the countries were mostly involved in outbreaks in neonatal intensive

160 care units (NICU) ⁴⁰⁻⁴⁵.

161 Carbapenem resistance among infants in the various countries were substantial, particularly

162 in India, Pakistan, China, Egypt, Taiwan, Thailand, and USA whilst polymyxin resistance

163 rate in infants was high in Thailand, India, Malaysia, and Nepal. In pregnant women, Algeria,

164 Madagascar, and Mexico recorded the highest number of CR-GNB colonizations (Figure 3).

165 ***Carbapenem & polymyxin resistance determinants***

166 Carbapenem resistance among CR-GNB in both infants and pregnant women were mainly
167 mediated by carbapenemases in all countries, with few reports of non-carbapenemases such
168 as ompK35 and ompK36 porins loss (Italy), penicillin-binding protein mutations (PBP3)
169 (Malaysia), OXA-1 β -lactamase (China), and soxS and marA efflux regulators (Malaysia),
170 mediating carbapenem resistance. GES-5 (Poland), IMP (Japan and China), and VIM (Italy,
171 Hungary, and Morocco) carbapenemases were mainly dominant in single or few countries or
172 regions (such as the Mediterranean region) whilst NDM, KPC, and OXA-48-like variants
173 were common in many countries among infants and pregnant women. Polymyxin resistance
174 mechanisms were largely not described in the included studies, except in one study by Naha
175 et al. (2020) in which overexpression of acrB, tolC, ramA, and soxS were found to mediate
176 colistin resistance³⁶ and in another study by Zeng et al. (2016) in which *mcr-I* was found in
177 an *Enterobacter* (now *Klebsiella*) *aerogenes* isolate (Figure 3).

178 ***Risk factors and mortality rates***

179 Risk factors associated with CR-GNB and PR-GNB infections and colonization differed
180 slightly between countries, with factors such as previous and/or long hospitalization, previous
181 and/or ongoing antibiotic therapy, invasive procedures such as caesarian section, intubation,
182 and catheterization, preterm and low birth weight infants, and mechanical ventilation being
183 common risk factors in almost all countries. Whereas PR-GNB-associated mortalities were
184 not reported, CR-GNB-associated mortalities were above 10% in Brazil, China, Egypt,
185 Hungary, and Thailand and noticeably lower than 10% in India, Nepal, Turkey, Pakistan,
186 Italy, and Cambodia.

187 **Discussion**

188 Carbapenem- and/or polymyxin-resistant GNB are common in neonates and pregnant women
189 in several countries as either infections or colonizations, threatening the lives of the affected
190 patients as CR-GNB and PR-GNB are associated with longer hospitalization and higher
191 morbidities and mortalities^{29,46–48}. Worryingly, many of the studies involved in this review
192 reported on clonal and polyclonal outbreaks and infections of CR-GNB or PR-GNB among
193 neonates in NICUs or colonization of CR-GNB in pregnant women involving pathogenic
194 GNB such as *A. baumannii*, *E. coli*, *Enterobacter sp.*, *K. pneumoniae*, and *P. aeruginosa*
195 (Tables S1-S3). In most of these CR-GNB, carbapenemases, including NDM, OXA-48,
196 KPC, VIM, IMP, and GES-5 were found on mobile plasmids within transposons, insertion
197 sequences, and integrons.

198 Notably, carbapenem-resistant *A. baumannii*, *E. coli*, and *K. pneumoniae* harbouring mobile
199 plasmid-borne carbapenemases cause outbreaks in neonates with sepsis, pneumonia, and
200 other infections in NICUs in several countries worldwide, resulting in very high mortalities
201 (Table S1)^{17,43,49–51}. For instance, carbapenem-resistant *A. baumannii* outbreaks were
202 reported by Lee et al. (2018), Sultan and Seliem (2018), Indhar et al. (2017), Al-lawama et al.
203 (2016), Thatrimontrichai et al. (2015), Kumar et al. (2014), and Tekin et al. (2013) in Taiwan,
204 Egypt, Pakistan, Jordan, Greece, India, and Turkey respectively, killing several infants^{19,51–}
205 ⁵⁶. *E. coli* neonatal infections and outbreaks were reported in Japan with an IMP-11
206 carbapenemase³⁷, in China with nine NDM-5-producing ST410 strains⁴⁵ and NDM-5-
207 positive ST167³³, in Turkey with an OXA-48-producing strain⁴³, and in India with NDM-1-
208 positive clonal strains from the body of infants and the ward environment⁴². Comparatively,
209 outbreaks in NICUs involving *K. pneumoniae* were globally reported, involving NICUs
210 infections, colonizations, mobile plasmid-borne *bla*_{NDM}, *bla*_{KPC}, *bla*_{OXA-48}, *bla*_{IMP}, *bla*_{VIM} and
211 *bla*_{GES-5} carbapenemases, and very high mortalities, making *K. pneumoniae* the most deadly
212 and common neonatal MDR pathogen^{13,18,25,27,28,31,36,40,41,43,44,49,50,57–63}.

213 Similarly, PR-GNB infections were also common in the same species viz., *A. baumannii*, *E.*
214 *coli*, *K. pneumoniae*, *Enterobacter sp.* and *Pseudomonas sp.*, although reports on outbreaks
215 were either associated with carbapenem resistance^{34,36} or absent. Hence, outbreaks involving
216 CR-GNB that were also polymyxin resistant could also be referred to as PR-GNB outbreaks,
217 which makes such infections very difficult to manage^{1,2,4,9}. The largest collection of PR-
218 GNB was recorded in Malaysia from preterm infants in a NICU in 2016, eight of which were
219 carbapenem-resistant *K. pneumoniae*³⁴. A colistin-resistant *C. freundii* isolate was
220 subsequently isolated from the stool of a preterm infant in the same hospital in Malaysia,
221 suggesting the persistence of PR-GNB in that setting⁶⁴. Naha et al. (2020) observed that
222 overexpression of *acrB*, *tolC*, *ramA*, and *soxS* conferred colistin resistance in a carbapenem-
223 resistant *K. pneumoniae* ST147, which could have been the resistance mechanism in the *C.*
224 *freundii* isolate from Malaysia^{36,64}. Although *mcr* genes, and not chromosomal mutations, are
225 the most common mechanisms mediating polymyxin resistance globally^{1,2,4,9}, an *mcr-1* was
226 only identified in one study (in *E. aerogenes*, now *K. aerogenes*) and interestingly, from the
227 vaginal secretions of a pregnant woman³⁹.

228 Hence, vaginal swabbing could also be used to screen for CR/PR-GNB in pregnant women
229 besides rectal swabbing as such important pathogens can be missed if they do not occur in the
230 gut. Further, the presence of CR/PR-GNB in the vagina could explain the colonization of
231 infants and wards with these MDR pathogens as they can pick up these bacteria during birth
232^{39,42}. If gut colonization of pregnant women with CR-GNB could potentially lead to
233 colonization and/or infection of the neonate^{22,24,65}, then vaginal colonization could even lead
234 to a more direct effect than gut colonization, making vaginal screening of pregnant women an
235 important means of preventing CR/PR-GNB infections and mortalities in neonates. The
236 means by which infants become colonized by CR/PR-GNB remains enigmatic, although
237 direct inoculation from mothers is highly likely. Nevertheless, neonatal colonization with

238 CR/PR-GNB is not only obtained from the mother as observed by other clinicians
239 ^{20,23,26,42,61,66,67} .

240 In particular, neonates can become colonized and later infected with CR/PR-GNB during
241 antibiotic therapy ^{23,68} , long-stay in wards (NICU) with endemic CR/PR-GNB ^{42,67} , handling
242 by healthcare workers, breastfeeding by colonized mothers, intubation, during labour or
243 caesarian section ^{24,65,66} , mechanized ventilation, from the community ^{23,61} etc. (Tables S1-
244 S3). To establish a direct relationship between mother and infant colonization, and with
245 infant colonization and infection, then a clonal analyses of isolates would have to be
246 undertaken. As yet, studies showing this clonal relationship between GNB isolates from
247 mother and neonate, and between neonate colonization and infection, are wanting (Figure 2).
248 Despite the larger number of studies reporting on pregnant women colonization, there are
249 relatively few reports of pregnant women infection with CR/-PR-GNB, suggesting that
250 colonization does not necessarily lead to infections in pregnant women or that their stronger
251 and much developed immune system makes them less susceptible to CR/PR-GNB infections.
252 Hence, CR/PR-GNB colonization in pregnant women is more of a risk to neonates than to the
253 women themselves. Nevertheless, infection of pregnant women with CR/PR-GNB could
254 complicate their pregnancies and put their lives at risk ⁴⁶ .

255 The clonality of the species infecting both pregnant women and infants were not the same,
256 suggesting little dissemination between colonized mothers and neonates. Further, there were
257 very few clones of *K. pneumoniae* that were seen in at most three countries, with almost all
258 the reported clones of all the species being local and restricted to single hospitals and wards
259 (Figure 2; Tables S1-S3). This demonstrates limited circulation of the same clone even within
260 a community, ward, hospital or country.

261 The carbapenemases found in the CR-GNB isolates mirrored those found in the same
262 countries and regions (Figure 4). For instance, IMP and VIM are common in Japan/China and
263 Italy (Europe) respectively, OXA-48 is common in the mediterranean region, Middle-East
264 and South Africa whilst KPC and NDM are globally distributed ⁶⁹. This global epidemiology
265 of carbapenemases is reflected in the epidemiology of carbapenemases in the infants and
266 pregnant women (Figure 4), further corroborating the localized transmission of CR-GNB in
267 neonates. In addition, the higher prevalence of NDM, KPC, and OXA-48-like
268 carbapenemases over VIM and IMP ⁶⁹, also reflects the global prevalence of these β -
269 lactamases in neonates (Figure 4). The carbapenemases were mainly found on mobile
270 plasmids (IncFII, IncX₃, IncN), integrons (*IntI1*), insertion sequences (*ISKpn7*, *ISKpn6*,
271 *ISAbal25*, *IS26*) and transposons (*Tn4401b*), which facilitates their movement from
272 chromosomes to plasmids, plasmids to plasmids, and between cells of the same or different
273 species ^{13,20,26,31,32,36,37,42,45,60,70} .

274 Specifically, NDM-5 carbapenemases were found on IncX₃ and IncFII plasmids in *K.*
275 *quasipneumoniae* ST476 (in Nigeria) and *E. coli* ST410 (in China) respectively, which were
276 causing outbreaks in NICUs. The immediate genetic environment of the NDM-5 on these
277 plasmids were exactly the same or similar, suggesting that same plasmids and/or clones were
278 mediating the spread of NDM-5 within and between species ^{31,45}. The higher mobility of
279 these carbapenemases may explain their faster dissemination between neonates in wards and
280 hospitals during outbreaks and evinces the need to undertake molecular analyses of isolates to
281 comprehend their epidemiology ^{1,2,4,9,69} .

282 Not all CR-GNB isolates contained carbapenemases. Isolates without carbapenemases, but
283 with ESBLs such as CTX-M, TEM, SHV, and OXA, coupled with the loss or downregulation
284 of porins ompK35 and ompK36, had very high resistance to carbapenems ^{27,44,59}. In Italy,
285 such strains resulted in mortalities as high as 28.5% ⁵⁹ .

286 Prevalence of CR/PR-GNB and carbapenemases were higher in countries with higher GNB
287 isolation rates (Figure 3-4), which is expected as most clinical investigations are undertaken
288 in response to increasing infections or outbreaks. Further, susceptible GNB are hardly
289 published except when they are isolated together with resistant GNB, making the literature
290 skewed towards resistant GNB cases. Higher reports of carbapenemases were observed in
291 China, India, Ghana, Italy, Hungary, Turkey, South Africa, Algeria and Madagascar (in
292 pregnant women), which does not fully reflect the carbapenem resistance rates shown in
293 Figure 3 as not all studies investigated the underlying carbapenem resistance mechanism. For
294 instance, Cambodia, Egypt, Greece, Pakistan, Taiwan, Thailand, and USA had higher
295 resistance rates, but very few or no report of carbapenemases. Whereas this may be due to
296 financial limitations in low- and middle-income countries (LMICs), the same can not be true
297 of wealthier countries such as Taiwan, Thailand, and the USA. Hence, there is the need for
298 increasing awareness among clinicians and researchers on the need to undertake advanced
299 genomics analyses of resistant GNB to facilitate epidemiological analyses and interventions.

300 On the other hand, countries with higher prevalence of carbapenemases and carbapenem
301 resistance rates should immediately institute effective infection control and prevention
302 practices as sufficient evidence indicates that this can both prevent and contain CR/PR-GNB
303 outbreaks^{41,63}. Particularly, the nosocomial colonization of neonates with clonally related
304 carbapenemase-producing *P. aeruginosa* in a NICU and the subsequent isolation of a VIM-
305 14 carbapenemase in the same pathogen in a NICU, both in Italy^{71,72}, depict the endemic
306 presence of this carbapenemase-producing pathogen within those periods in the affected
307 regions. This signals the urgency required in instituting effective interventions to clear these
308 MDR pathogens and save further lives as outbreaks in NICUs are associated with very high
309 mortalities^{29,50,54}.

310 Common risk factors for getting CR/PR-GNB infections across all countries have been stated
311 above: they include include colonization of the infant or mother with CR/PR-GNB, long-term
312 hospitalization in NICUs, undergoing invasive procedures and previous, ongoing or longer
313 antibiotic therapy, mechanical ventilation, preterm state, and low birth weight (Fig. 5)^{22,55,57}.
314 Interestingly, neonatal colonization with CR/PR-GNB during NICU stay can later result in
315 community and nosocomial infections as described by Vergadi et al. (2017)⁶¹. Sadly, infant
316 mortalities from CR/PR-GNB remains substantially high in many countries, including China
317 and Brazil (Fig. 6), albeit treatment with carbapenems (at higher doses), colistin, and
318 tigecycline have been shown to be very efficient in clearing the infection and saving lives
319 ^{7,10,28,45,56,73}. Instructively, Kumar et al. (2014) observed that the absence of effective
320 treatment led to higher all-cause mortalities in neonates⁵⁴.

321 ***Conclusion and future perspectives***

322 Evidently, carbapenem and polymyxin resistance is common in GNB isolated from infants
323 and pregnant women, with high resistance rates and diverse carbapenemases globally,
324 particularly in India, China, Pakistan, Thailand, Algeria, South Africa, Turkey, Ghana,
325 Hungary, and Italy. In almost all these countries, there were local clonal outbreaks involving
326 *A. baumannii*, *E. coli*, *Enterobacter sp.*, *K. pneumoniae*, and *P. aeruginosa* clones hosting
327 mobile plasmids, integrons, insertion sequences, and transposons on which were found
328 *bla*_{NDM}, *bla*_{KPC}, *bla*_{OXA-48}, *bla*_{IMP}, *bla*_{VIM} and *bla*_{GES-5} carbapenemases. Whereas colonization
329 in pregnant women is a risk factor for neonatal infections and outbreaks, infections in
330 pregnant women can complicate their pregnancies. Infection with CR/PR-GNB has been
331 associated with very high mortality rates among infants, necessitating urgent infection control
332 interventions to prevent further outbreaks and safeguard lives. The commonality of risk
333 factors for getting CR/PR-GNB infections in all countries indicate that adopting a standard
334 and strict infection control measures in all healthcare centres globally can contain these

335 pathogens from causing further infections. Several outbreaks have been contained with strict
336 infection control interventions.

337 Fortunately, treatment of CR/PR-GNB infections is possible with polymyxins, higher doses
338 of carbapenems, tigecycline, amikacin, and avibactam/sulbactam-cephalosporin/carbapenem
339 combinations. Such treatment protocols and medicines must be distributed to all
340 paediatricians and enforced to reduce infant mortalities. Nevertheless caution with antibiotic
341 therapy (stewardship) must be also advised as it is a risk factor for acquired carbapenem
342 resistance colonization or infection.

343 Going forward, periodic genomic (molecular) surveillance/screening of hospitals (wards) and
344 patients must be instituted to pre-emptively identify patients with CR/PR-GNB infections or
345 colonization. Particularly, vaginal and rectal screening of pregnant women can help in
346 surveillance exercises. Further genomic analyses to identify the clones, plasmids, and
347 resistance mechanisms shall inform the appropriate intervention to adopt to break the chain of
348 transmission.

349 **Acknowledgments:** None

350 **Funding:** None

351 **Transparency declaration:** None

352 **References**

- 353 1. Osei Sekyere, J. & Reta, M. A. Genomic and Resistance Epidemiology of Gram-Negative Bacteria in
354 Africa: a Systematic Review and Phylogenomic Analyses from a One Health Perspective. *mSystems* **5**,
355 (2020).
- 356 2. Kopotsa, K., Mbelle, N. M. & Osei Sekyere, J. Epigenomics, Genomics, Resistome, Mobilome,
357 Virulome and Evolutionary Phylogenomics of Carbapenem-resistant *Klebsiella pneumoniae* clinical
358 strains. *Microb. genomics genomics* (2020). doi:10.1101/2020.06.20.20135632
- 359 3. Osei Sekyere, J. & Mensah, E. Molecular epidemiology and mechanisms of antibiotic resistance in

- 360 Enterococcus spp., Staphylococcus spp., and Streptococcus spp. in Africa: a systematic review from a
361 One Health perspective. *Ann. N. Y. Acad. Sci.* **1465**, 29–58 (2020).
- 362 4. Osei Sekyere, J., Maningi, N. E., Modipane, L. & Mbelle, N. M. Emergence of mcr-9.1 in ESBL-
363 producing Clinical Enterobacteriaceae in Pretoria, South Africa: Global Evolutionary Phylogenomics,
364 Resistome and Mobilome. *mSystems* **5**, e00148-20 (2020).
- 365 5. Van Boeckel, T. P. *et al.* Global trends in antimicrobial resistance in animals in low- and middle-income
366 countries. *Science (80-.)*. **365**, eaaw1944 (2019).
- 367 6. Osei Sekyere, J., Govinden, U., Bester, L. A. & Essack, S. Y. Colistin and Tigecycline Resistance In
368 Carbapenemase-Producing Gram Negative Bacteria: Emerging Resistance Mechanisms And Detection
369 Methods. *J. Appl. Microbiol.* **121**, 601–617 (2016).
- 370 7. Cagan, E., Kiray Bas, E. & Asker, H. S. Use of Colistin in a Neonatal Intensive Care Unit: A Cohort
371 Study of 65 Patients. *Med. Sci. Monit.* **23**, 548–554 (2017).
- 372 8. Osei Sekyere, J. Current State of Resistance to Antibiotics of Last-Resort in South Africa: A Review
373 from a Public Health Perspective. *Front. Public Heal.* **4**, 209 (2016).
- 374 9. Mmatli, M., Mbelle, N. M., Maningi, N. E. & Osei Sekyere, J. Emerging Transcriptional and Genomic
375 Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae: a Systematic
376 Review of Current Reports. *mSystems* **5**, (2020).
- 377 10. Almohammady, M. N., Eltahlawy, E. M. & Reda, N. M. Pattern of bacterial profile and antibiotic
378 susceptibility among neonatal sepsis cases at Cairo University Children Hospital. *J. Taibah Univ. Med.*
379 *Sci.* **15**, 39–47 (2020).
- 380 11. Karaaslan, A. *et al.* Intravenous Colistin Use for Multidrug-Resistant Gram-Negative Infections in
381 Pediatric Patients. *Balkan Med. J.* **33**, 627–632 (2016).
- 382 12. Mularoni, A. *et al.* Epidemiology and successful containment of a carbapenem-resistant
383 Enterobacteriaceae outbreak in a Southern Italian Transplant Institute. *Transpl. Infect. Dis.* **21**, e13119
384 (2019).
- 385 13. Ahmad, N., Ali, S. M. & Khan, A. U. Molecular characterization of novel sequence type of
386 carbapenem-resistant New Delhi metallo-beta-lactamase-1-producing *Klebsiella pneumoniae* in the
387 neonatal intensive care unit of an Indian hospital. *Int. J. Antimicrob. Agents* **53**, 525–529 (2019).
- 388 14. Aguilera-Alonso, D., Escosa-García, L., Saavedra-Lozano, J., Cercenado, E. & Baquero-Artigao, F.
389 Carbapenem-resistant Gram-negative bacterial infections in children. *Antimicrobial Agents and*
390 *Chemotherapy* **64**, (2020).
- 391 15. Tacconelli, E. *et al.* Discovery, research, and development of new antibiotics: the WHO priority list of
392 antibiotic-resistant bacteria and tuberculosis. *Lancet. Infect. Dis.* **18**, 318–327 (2018).
- 393 16. Asokan, G. V, Ramadhan, T., Ahmed, E. & Sanad, H. WHO Global Priority Pathogens List: A

- 394 Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and
395 Control Practices in Bahrain. *Oman Med. J.* **34**, 184–193 (2019).
- 396 17. Jajoo, M. *et al.* Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in
397 North India. *PLoS One* **13**, e0180705 (2018).
- 398 18. Essel, V. *et al.* A multisectoral investigation of a neonatal unit outbreak of *Klebsiella pneumoniae*
399 bacteraemia at a regional hospital in Gauteng Province, South Africa. *South African Med. J.* **110**, 783–
400 790 (2020).
- 401 19. Thatrimontrichai, A. *et al.* Risk factors and outcomes of carbapenem-resistant *Acinetobacter baumannii*
402 ventilator-associated pneumonia in the neonate: A case-case-control study. *J. Infect. Chemother.* **22**,
403 444–449 (2016).
- 404 20. Ahmad, N., Khalid, S., Ali, S. M. & Khan, A. U. Occurrence of blaNDM Variants Among
405 Enterobacteriaceae From a Neonatal Intensive Care Unit in a Northern India Hospital. *Front.*
406 *Microbiol.* **9**, 407 (2018).
- 407 21. Chabah, M. *et al.* Healthcare-associated infections due to carbapenemase-producing Enterobacteriaceae:
408 Bacteriological profile and risk factors. *Med. Mal. Infect.* **46**, 157–162 (2016).
- 409 22. Chereau, F. *et al.* Colonization of extended-spectrum- β -lactamase- and NDM-1-producing
410 Enterobacteriaceae among pregnant women in the community in a low-income country: A potential
411 reservoir for transmission of multiresistant Enterobacteriaceae to neonates. *Antimicrob. Agents*
412 *Chemother.* **59**, 3652–3655 (2015).
- 413 23. Clock, S. A. *et al.* Colonization With Antimicrobial-Resistant Gram-Negative Bacilli at Neonatal
414 Intensive Care Unit Discharge. **6**, 219–226 (2017).
- 415 24. Mairi, A. *et al.* Carbapenemase-producing Enterobacteriaceae among pregnant women and newborns in
416 Algeria: Prevalence, molecular characterization, maternal-neonatal transmission, and risk factors for
417 carriage. *Am. J. Infect. Control* **47**, 105–108 (2019).
- 418 25. Literacka, E. *et al.* Spread of *Klebsiella pneumoniae* ST45 Producing GES-5 Carbapenemase or GES-1
419 Extended-Spectrum β -Lactamase in Newborns and Infants. *Antimicrobial agents and chemotherapy* **64**,
420 6–9 (2020).
- 421 26. Arhoune, B. *et al.* Rectal carriage of extended-spectrum beta-lactamase- and carbapenemase-producing
422 Enterobacteriaceae among hospitalised neonates in a neonatal intensive care unit in Fez, Morocco. *J.*
423 *Glob. Antimicrob. Resist.* **8**, 90–96 (2017).
- 424 27. Datta, S. *et al.* A five-year experience of carbapenem resistance in Enterobacteriaceae causing neonatal
425 septicaemia: predominance of NDM-1. *PLoS One* **9**, e112101 (2014).
- 426 28. Huang, X. *et al.* Characteristics of NDM-1-producing *Klebsiella pneumoniae* ST234 and ST1412
427 isolates spread in a neonatal unit. *BMC Microbiol.* **18**, 186 (2018).

- 428 29. Johnson, J. *et al.* High Burden of Bloodstream Infections Associated With Antimicrobial Resistance and
429 Mortality in the Neonatal Intensive Care Unit in Pune, India. *Clin. Infect. Dis.* (2020).
430 doi:10.1093/cid/ciaa554
- 431 30. Liu, J. *et al.* Emergence and establishment of KPC-2-producing ST11 Klebsiella pneumoniae in a
432 general hospital in Shanghai, China. *Eur. J. Clin. Microbiol. Infect. Dis.* **37**, 293–299 (2018).
- 433 31. Brinkac, L. M. *et al.* Emergence of New Delhi Metallo-beta-Lactamase (NDM-5) in Klebsiella
434 quasipneumoniae from Neonates in a Nigerian Hospital. *mSphere* **4**, (2019).
- 435 32. Islam, M. A. *et al.* Occurrence and characterization of multidrug-resistant New Delhi metallo-beta-
436 lactamase-1-producing bacteria isolated between 2003 and 2010 in Bangladesh. *J. Med. Microbiol.* **62**,
437 62–68 (2013).
- 438 33. Zhu, Y.-Q. *et al.* Identification of an NDM-5-producing Escherichia coli Sequence Type 167 in a
439 Neonatal Patient in China. *Sci. Rep.* **6**, 29934 (2016).
- 440 34. Yap, P. S. X. *et al.* Intestinal carriage of multidrug-resistant gram-negative bacteria in preterm-infants
441 during hospitalization in neonatal intensive care unit (NICU). *Pathog. Glob. Health* **110**, 238–246
442 (2016).
- 443 35. Soo, P. *et al.* Intestinal carriage of multidrug-resistant gram-negative bacteria in preterm-infants during
444 hospitalization in neonatal intensive care unit (NICU). *Pathog. Glob. Health* **110**, 1–9 (2016).
- 445 36. Naha, S. *et al.* KPC-2-producing Klebsiella pneumoniae ST147 in a neonatal unit: Clonal isolates with
446 differences in colistin susceptibility attributed to AcrAB-TolC pump. *Int. J. Antimicrob. Agents* **55**,
447 105903 (2020).
- 448 37. Zhao, W., Chen, G., Ito, R., Kimura, S. & Hu, Z. Identification of a plasmid-borne bla IMP-11 gene in
449 clinical isolates of Escherichia coli and Klebsiella pneumoniae. 246–251 (2012).
450 doi:10.1099/jmm.0.035626-0
- 451 38. Ding, Y., Wang, Y., Hsia, Y., Sharland, M. & Heath, P. T. Systematic review of carbapenem-resistant
452 Enterobacteriaceae causing neonatal sepsis in China. *Ann. Clin. Microbiol. Antimicrob.* **18**, 36 (2019).
- 453 39. Zeng, K.-J., Doi, Y., Patil, S., Huang, X. & Tian, G.-B. Emergence of the Plasmid-Mediated mcr-1
454 Gene in Colistin-Resistant Enterobacter aerogenes and Enterobacter cloacae. *Antimicrob. Agents
455 Chemother.* **60**, 3862–3863 (2016).
- 456 40. Zheng, R. *et al.* Outbreak of plasmid-mediated NDM-1-producing Klebsiella pneumoniae ST105 among
457 neonatal patients in Yunnan, China. *Ann. Clin. Microbiol. Antimicrob.* **15**, 10 (2016).
- 458 41. Yu, J. *et al.* Nosocomial outbreak of KPC-2- and NDM-1-producing Klebsiella pneumoniae in a
459 neonatal ward: a retrospective study. *BMC Infect. Dis.* **16**, 563 (2016).
- 460 42. Roy, S., Singh, A. K., Viswanathan, R., Nandy, R. K. & Basu, S. Transmission of imipenem resistance
461 determinants during the course of an outbreak of NDM-1 Escherichia coli in a sick newborn care unit.

- 462 2773–2780 (2011). doi:10.1093/jac/dkr376
- 463 43. Poirel, L. *et al.* Spread of NDM-1-producing Enterobacteriaceae in a neonatal intensive care unit,
464 Istanbul, Turkey. *Antimicrob Agents Chemother* AAC. 02047-13 (2014).
- 465 44. Jin, Y. *et al.* Outbreak of Multidrug Resistant NDM-1- Producing Klebsiella pneumoniae from a
466 Neonatal Unit in Shandong Province , China. 1–11 (2015). doi:10.1371/journal.pone.0119571
- 467 45. Li, J. *et al.* Emergence of an NDM-5-producing Escherichia coli sequence type 410 clone in infants in a
468 children’s hospital in China. *Infect. Drug Resist.* **13**, 703–710 (2020).
- 469 46. Khatri, A. *et al.* Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing
470 Klebsiella pneumoniae. *Antimicrob. Agents Chemother.* **59**, 4375–4378 (2015).
- 471 47. Macharashvili, N. *et al.* Etiology of neonatal blood stream infections in Tbilisi, Republic of Georgia. *Int.*
472 *J. Infect. Dis.* **13**, 499–505 (2009).
- 473 48. Mairi, A., Pantel, A., Sotto, A., Lavigne, J.-P. & Touati, A. OXA-48-like carbapenemases producing
474 Enterobacteriaceae in different niches. *Eur. J. Clin. Microbiol. Infect. Dis.* **37**, 587–604 (2018).
- 475 49. Stoesser, N. *et al.* Genome sequencing of an extended series of NDM-producing Klebsiella pneumoniae
476 isolates from neonatal infections in a Nepali hospital characterizes the extent of community- versus
477 hospital-associated transmission in an endemic setting. *Antimicrob. Agents Chemother.* **58**, 7347–7357
478 (2014).
- 479 50. Saleem, A. F., Qamar, F. N., Shahzad, H., Qadir, M. & Zaidi, A. K. M. Trends in antibiotic
480 susceptibility and incidence of late-onset Klebsiella pneumoniae neonatal sepsis over a six-year period
481 in a neonatal intensive care unit in Karachi, Pakistan. *Int. J. Infect. Dis.* **17**, e961–e965 (2013).
- 482 51. Sultan, A. M. & Seliem, W. A. Identifying risk factors for healthcare-associated infections caused by
483 carbapenem-resistant acinetobacter baumannii in a neonatal intensive care unit. *Sultan Qaboos Univ.*
484 *Med. J.* **18**, e75–e80 (2018).
- 485 52. Indhar, F., Durrani, M. A., Bux, A. & Sohail, M. care hospital in Karachi Carbapenemases among
486 Acinetobacter species isolated from NICU of a tertiary care hospital in Karachi. (2017).
- 487 53. Al-lawama, M., Aljbour, H., Tanash, A. & Badran, E. Intravenous Colistin in the treatment of
488 multidrug-resistant Acinetobacter in neonates. *Ann. Clin. Microbiol. Antimicrob.* **15**, 1–4 (2016).
- 489 54. Kumar, A., Randhawa, V. S., Nirupam, N., Rai, Y. & Saili, A. Risk factors for carbapenem-resistant
490 Acinetobacter baumannii blood stream infections in a neonatal intensive care unit, Delhi, India. *J. Infect.*
491 *Dev. Ctries.* **8**, 1049–1054 (2014).
- 492 55. Lee, H. Y. *et al.* Risk factors and molecular epidemiology of Acinetobacter baumannii bacteremia in
493 neonates. *J. Microbiol. Immunol. Infect.* **51**, 367–376 (2018).
- 494 56. Tekin, R., Dal, T., Pirinccioglu, H. & Oygucu, S. E. A 4-year surveillance of Device-Associated
495 nosocomial infections in a neonatal intensive care unit. *Pediatr. Neonatol.* **54**, 303–308 (2013).

- 496 57. Li, P. *et al.* ST37 *Klebsiella pneumoniae*: development of carbapenem resistance in vivo during
497 antimicrobial therapy in neonates. *Future Microbiol.* **12**, 891–904 (2017).
- 498 58. Chen, D. *et al.* Co-outbreak of multidrug resistance and a novel ST3006 *Klebsiella pneumoniae* in a
499 neonatal intensive care unit: A retrospective study. *Medicine (Baltimore)*. **98**, e14285 (2019).
- 500 59. Arena, F. *et al.* Large oligoclonal outbreak due to *klebsiella pneumoniae* ST14 and ST26 producing the
501 FOX-7 AmpC β -lactamase in a neonatal intensive care unit. *J. Clin. Microbiol.* **51**, 4067–4072 (2013).
- 502 60. Yu, J. *et al.* Outbreak of nosocomial NDM-1-producing *Klebsiella pneumoniae* ST1419 in a neonatal
503 unit. *J. Glob. Antimicrob. Resist.* **8**, 135–139 (2017).
- 504 61. Vergadi, E., Bitsori, M., Maraki, S. & Galanakis, E. Community-onset carbapenem-resistant *Klebsiella*
505 *pneumoniae* urinary tract infections in infancy following NICU hospitalisation. *J. Pediatr. Urol.* **13**,
506 495.e1-495.e6 (2017).
- 507 62. Liu, Y. *et al.* Acquisition of carbapenem resistance in multiresistant *Klebsiella pneumoniae* isolates of
508 sequence type 11 at a university hospital in China. *Diagn. Microbiol. Infect. Dis.* **76**, 241–243 (2013).
- 509 63. Kong, Z. *et al.* First reported nosocomial outbreak of NDM-5-producing *Klebsiella pneumoniae* in a
510 neonatal unit in China. *Infect. Drug Resist.* **12**, 3557–3566 (2019).
- 511 64. Yap, P. S. X., Ahmad Kamar, A., Chong, C. W., Yap, I. K. S. & Teh, C. S. J. Whole genome analysis of
512 multidrug resistant *Citrobacter freundii* B9-C2 isolated from preterm neonate's stool in the first week. *J.*
513 *Glob. Antimicrob. Resist.* **21**, 246–251 (2020).
- 514 65. Rawstron, S. A. *et al.* Perirectal Screening for Carbapenem-Resistant Enterobacteriaceae Obtained From
515 100 Consecutive Healthy Pregnant Women in Labor at a Brooklyn Hospital: Results and Risk Factors.
516 *Infect. Control Hosp. Epidemiol.* **39**, 369–371 (2018).
- 517 66. Kothari, C. *et al.* Community acquisition of beta-lactamase producing Enterobacteriaceae in neonatal
518 gut. *BMC Microbiol.* **13**, 136 (2013).
- 519 67. Turner, P., Neou, L. & Turner, C. High Prevalence of Antimicrobial-resistant Gram-negative
520 Colonization in Hospitalized Cambodian Infants. **35**, 856–861 (2016).
- 521 68. Zhu, J. *et al.* *Klebsiella pneumoniae*: Development of carbapenem resistance due to acquisition of
522 blaNDM-1 during antimicrobial therapy in twin infants with pneumonia. *Front. Microbiol.* **6**, 1–5
523 (2015).
- 524 69. Kopotsa, K., Osei Sekyere, J. & Mbelle, N. M. Plasmid evolution in carbapenemase-producing
525 Enterobacteriaceae: a review. *Ann. New* **1457**, 61–91 (2019).
- 526 70. Xu, J., Lin, W., Chen, Y. & He, F. Characterization of an imp-4-producing *klebsiella pneumoniae*
527 st1873 strain recovered from an infant with a bloodstream infection in china. *Infect. Drug Resist.* **13**,
528 773–779 (2020).
- 529 71. Mammina, C. *et al.* Nosocomial colonization due to imipenem-resistant *Pseudomonas aeruginosa*

- 530 epidemiologically linked to breast milk feeding in a neonatal intensive care unit. **29**, 1486–1492 (2008).
- 531 72. Mazzariol, A. *et al.* A novel VIM-type metallo-beta-lactamase (VIM-14) in a *Pseudomonas aeruginosa*
532 clinical isolate from a neonatal intensive care unit. *Clin. Microbiol. Infect.* **17**, 722–724 (2011).
- 533 73. Choudhry, S., Ahmad, E., Batool, A. & Raja, N. Use of colistin for the treatment of multi drug resistant
534 isolates in neonates. **67**, 1157–1160 (2017).

535

536 **Figure 1. Count and isolation rates of Gram-negative bacterial species obtained from**
537 **pregnant women and infants per country. A-D** shows the count and isolation rates of
538 carbapenem-resistant Gram-negative bacteria isolated from infants per country, **E** shows the
539 count and isolation rates of CR-GNB in pregnant women whilst **F** shows the count of
540 polymyxin-resistant GNB in infants.

541 **Figure 2. Count of Gram-negative bacteria clones infecting or colonizing infants and**
542 **pregnant women per country. A-B** shows count and prevalence of clones isolated from
543 infants and **C** shows clones isolated from pregnant women.

544 **Figure 3. Carbapenem and polymyxin resistance rates in Gram-negative bacteria**
545 **isolated from infants and pregnant women. A and B** show carbapenem resistance rates
546 from infants and pregnant women respectively, and **C** shows polymyxin resistance rates per
547 country.

548 **Figure 4. Carbapenemases detected in Gram-negative bacteria per country. A and B**
549 show carbapenemases detected in bacteria isolated from infants and **C** shows carbapenemases
550 obtained from pregnant women.

551 **Figure 5. Risk factors associated with carbapenem and polymyxin-resistant Gram-**
552 **negative bacteria in neonates and pregnant women. A-C** depict risks associated with
553 carbapenem resistance in neonates, **D** depict risks associated with carbapenem resistance in

554 pregnant women, and **E** depicts risks associated with polymyxin/colistin resistance in
555 neonates and pregnant women.

556 **Figure 6. Mortality rates associated with carbapenem resistance in infants per country.**

557 **Figure S1. Literature search strategy, inclusion and exclusion criteria employed to**
558 **arrive at the articles used in this study.**



559 **Figure S2. Isolation rate of Gram-negative bacterial species obtained from infants and**
560 **pregnant women per country. A** shows the isolation rate of Gram-negative bacteria
561 obtained from infants per country, **B** shows the isolation rate of Gram-negative bacteria
562 obtained from pregnant women per country, and **C** shows the isolation rate of polymyxin-
563 resistant Gram-negative bacteria obtained from infants per country,

564 **Supplemental Table 1.** Data on the epidemiology, risk factors, clinical outcomes, resistance
565 mechanisms, resistance rates, and prevalence of carbapenem-resistant Gram-negative bacteria
566 infecting or colonizing infants.


567 **Supplemental Table 2.** Data on the epidemiology, risk factors, clinical outcomes, resistance
568 mechanisms, resistance rates, and prevalence of carbapenem-resistant Gram-negative bacteria
569 infecting or colonizing pregnant women.

570 **Supplemental Table 3.** Data on the epidemiology, risk factors, clinical outcomes, resistance
571 mechanisms, resistance rates, and prevalence of polymyxin-resistant Gram-negative bacteria
572 infecting or colonizing infants and pregnant women.


573




A Carbapenem resistance rate of GNB among infants per country




B Carbapenem resistance rate of GNB among pregnant women per country




C Polymyxin resistance rate in GNB among infants per country




A Carbapenemase detection rate among infants per country








B Carbapenemase detection rate among infants per country




C Carbapenemase detection rate among pregnant women per country





Carbapenem resistance-associated infant mortality rates (%) per country






Figure S1: Flow diagram showing the results of the literature and database search strategy, inclusion, and exclusion criteria, with reasons.

